Understanding the Effects of Emerging Cellular, Molecular, and Genomic Technologies on Cancer Health Care Delivery(R01)

archived

-Purpose. This Funding Opportunity Announcement (FOA), issued by the National Cancer Institute (NCI), National Institutes of Health (NIH), invites grant applications for health services research that address the utilization of emerging cellular, molecular, and genetic or genomic (CMG) technologies in cancer care. The studies will assess CMG technologies in relation to: (a) quality of care; (b) organizational barriers and change factors in utilization; (c) cost and cost-effectiveness; (d) disparities in access and efficacy; (e) monitoring of cross-sectional patterns of care and time trends; (f) impact on existing standards of care; and (g) influence on cancer outcomes such as incidence, progression, mortality, survival, and quality of life. This FOA specifically encourages research on commercially available CMG clinical tools already in use, as well as experimental tools in the later stages of development and/or in the regulatory approval pipeline. The funding opportunity also encourages interdisciplinary collaborations between health services researchers and those in the clinical and/or translational sciences. -Mechanism of Support. This FOA utilizes the NIH Research Project Grant (R01 mechanism and runs in parallel with an FOA of identical scientific scope, PA-09-005 which uses the exploratory/developmental (R21) grant mechanism. -Funds Available and Anticipated Number of Awards. Awards issued under this FOA are contingent upon the availability of funds and the submission of a sufficient number of meritorious applications.

High